Last reviewed · How we verify
HSK39004 inhalation suspension — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
HSK39004 inhalation suspension (HSK39004 inhalation suspension) — Haisco Pharmaceutical Group Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HSK39004 inhalation suspension TARGET | HSK39004 inhalation suspension | Haisco Pharmaceutical Group Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HSK39004 inhalation suspension CI watch — RSS
- HSK39004 inhalation suspension CI watch — Atom
- HSK39004 inhalation suspension CI watch — JSON
- HSK39004 inhalation suspension alone — RSS
Cite this brief
Drug Landscape (2026). HSK39004 inhalation suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/hsk39004-inhalation-suspension. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab